References of "Maillard, N"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
Gauthier, J; Castagna, L; Garnier, F et al

in Bone Marrow Transplantation (in press)

Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed ... [more ▼]

Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N = 34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N = 31, 91%) or a RIC (N = 3, 9%) followed by post-transplant cyclophosphamide. After adjustment for significant covariates, MMUD and CB were associated with significantly lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR) = 2.02, P = 0.03 and HR = 2.43, P = 0.009, respectively) compared with HAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with posttransplant cyclophosphamide from HAPLO donors. Our findings suggest they should be favoured over MMUD and CB in this setting. [less ▲]

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailEffet of immune modulation in relapsed peripheral T cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Mamez; Levy, V; Chevallier, P et al

in Bone Marrow Transplantation (2016), 51

Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell ... [more ▼]

Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with nonimmunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68–48.21), P = 0.0009) and skin relapse (odds ratio: 4.15 (1.04–16.50), P = 0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17–0.640), P = 0.0009). This large series provides encouraging evidence of a true GvL effect in this disease. [less ▲]

Detailed reference viewed: 26 (0 ULg)
Full Text
Peer Reviewed
See detailManagement of myelodysplasic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies
Guièze, R; Damaj, G; Pereira, B et al

in Biology of Blood & Marrow Transplantation (2016), 22

To find out prognostic factors and to investigate different therapeutic approaches, we report on 147 consecutive patients who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT ... [more ▼]

To find out prognostic factors and to investigate different therapeutic approaches, we report on 147 consecutive patients who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS). Sixty-two patients underwent immunotherapy (IT group, second allo-HSCT or donor lymphocyte infusion), 39 received cytoreductive treatment alone (CRT group) and 46 were managed with palliative/supportive cares (PSC group). Two-year rates of overall survival (OS) were 32%, 6%, and 2% in the IT, CRT, and PSC groups, respectively (P < .001). In multivariate analysis, 4 factors adversely influenced 2-year rates of OS: history of acute graft-versus-host disease (hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.26 to 2.67; P ¼ .002), relapse within 6 months (HR, 2.69; 95% CI, .82 to 3.98; P < .001), progression to acute myeloid leukemia (HR, 2.59; 95% CI, 1.75 to 3.83; P < .001), and platelet count < 50 G/L at relapse (HR, 1.68; 95% CI, 1.15 to 2.44; P ¼.007). A prognostic score based on those factors discriminated 2 risk groups with median OSs of 13.2 versus 2.4 months, respectively (P < .001). When propensity score, prognostic score, and treatment strategy were included in Cox model, immunotherapy was found to be an independent factor that favorably impacts OS (HR, .40; 95% CI, .26 to .63; P < .001). In conclusion, immunotherapy should be considered when possible for MDS patients relapsing after allo-HSCT. [less ▲]

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailExploration de la fonction glomérulaire rénale : estimation du débit de filtration glomérulaire
Maillard, N; DELANAYE, Pierre ULg; Mariat, C

in Néphrologie & Thérapeutique (2015), 11(1), 54-67

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailKDIGO Guidelines and Kidney Transplantation: Is the cystatin-C Based Recommendation relevant?
Masson, I; Maillard, N; CAVALIER, Etienne ULg et al

in American Journal of Transplantation (2015), 15(8), 2211-4

The KDIGO guidelines propose a new approach to diagnose chronic kidney disease (CKD) based on estimated glomerular ®ltration rate (GFR). In patients with a GFR value comprised between 45 and 59 mL/ min/1 ... [more ▼]

The KDIGO guidelines propose a new approach to diagnose chronic kidney disease (CKD) based on estimated glomerular ®ltration rate (GFR). In patients with a GFR value comprised between 45 and 59 mL/ min/1.73m2 as estimated by the CKD-EPI creatinine equation (eGFRcreat), it is suggested to con®rm the diagnosis with a second estimation using the CKD-EPI cystatin C-based equations (eGFRcys/eGFRcreat-cys). We sought to determine whether this new diagnostic strategy might extend to kidney transplant recipients (KTR) and help to identify those with decreased GFR. In 670 KTR for whom a measured GFR was available, we simulated the detection of CKD using the two-steps approach recommended by the guidelines in comparison to the conventional approach relying on creatinine equation. One hundred forty-®ve patients with no albuminuria had eGFRcreat between 45 and 59 mL/ min/1.73m2. Among them, 23% had inulin clearance over 60 mL/min/1.73m2 and were thus incorrectly classi®ed as CKD patients. When applying the Kidney Disease: Improving Global Outcomes (KDIGO) strategy, 138 patients were con®rmed as having a GFR below 60 mL/min with eGFRcreat-cys. However, 21% of them were misclassi®ed in reference to measured GFR. Our data do no not support the use of cystatin C as a con®rmatory test of stage 3A CKD in KTR. [less ▲]

Detailed reference viewed: 33 (4 ULg)
Full Text
Peer Reviewed
See detailOutcomes of adults with active or progressive hematological malignancies at time of allogeneic stem cell transplantation : a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Chevallier, P.; Labopin, M.; Milpied, N. et al

in Bone Marrow Transplantation (2014), 49

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective ... [more ▼]

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective study aimed to analyze the outcome of adult patients who received allo-SCT in a chemo-refractory/relapsed status. The series included 840 patients with active or progressive disease at the time of transplant. Median age was 50 years. With a median follow-up of 40 months, 3-year OS, disease-free survival (DFS), and non-relapse mortality rates were 29±2, 23±2, and 30±2%, respectively. At the last follow-up, 252 patients (30%) were still alive (of whom 201 were in CR (24%). In a Cox multivariate analysis, the use of a reduced-intensity conditioning (RIC) before allo-SCT and use of an HLA-identical sibling donor remained independently associated with a better OS (hazard ratio (HR)¼0.82; 95% confidence interval (CI), 0.69–0.98, P¼0.03; and HR¼0.79; 95% CI, 0.66–0.93, P¼0.006, respectively). Also, a diagnosis of myelodysplastic syndrome/myeloproliferative disorder, Hodgkin lymphoma and non-Hodgkin lymphoma compared with acute leukemia had a favorable impact on OS (HR¼0.55; 95% CI, 0.45–0.68, Po0.0001; HR¼0.49; 95% CI, 0.31–0.75, P¼0.001; and HR¼0.47; 95% CI, 0.35–0.63, Po0.0001, respectively). In conclusion, this study suggests that allo-SCT may be of benefit in some subgroups of patients with active or progressive hematological malignancies at the time of allo-SCT. [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailMDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients
Masson, I; Flamant, M; Maillard, N et al

Poster (2013)

Detailed reference viewed: 11 (0 ULg)
Peer Reviewed
See detailNew K/DIGO guidelines and kidney transplantation: is the cystatin-C based recommendation relevant?
Masson, I; Maillard, N; DELANAYE, Pierre ULg

Conference (2013)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailNouvelles recommendations K/DIGO et transplantation rénale : quelle place pour la cystatine C ?
Masson, I; Maillard, N; Alamartine, E et al

Conference (2013)

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailNew K/DIGO guidelines and kidney transplantation: is the cystatin C-based recommendation relevant?
Masson, I; Maillard, N; Alamartine, E et al

Conference (2013)

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailDéterminant physiologique du NGAL sanguin et discordance entre NGAL sanguin et urinaire.
DELANAYE, Pierre ULg; Claisse, G; Mehdi, M et al

Poster (2013)

Detailed reference viewed: 12 (5 ULg)
Peer Reviewed
See detailDéterminant physiologique du NGAL sanguin et discordance entre NGAL sanguin et urinaire.
DELANAYE, Pierre ULg; Claisse, G; Mehdi, M et al

Poster (2013)

Detailed reference viewed: 15 (8 ULg)
Full Text
Peer Reviewed
See detailComparison of acid and enzymatic methods for insulin dosage: Analytical performances and impact on glomerular filtration rate evaluation
DELANAYE, Pierre ULg; Thibaudin, L.; Souvignet, M. et al

in Clinica Chimica Acta (2012), 413(5-6), 556-560

Among issues susceptible to hamper a reliable measurement of inulin clearance, those regarding the dosage of inulin are largely neglected. We have compared the analytical performances of 2 commonly used ... [more ▼]

Among issues susceptible to hamper a reliable measurement of inulin clearance, those regarding the dosage of inulin are largely neglected. We have compared the analytical performances of 2 commonly used methods of inulin dosage (one “acid” and one “enzymatic” method) and studied their potential impact on the glomerular filtration rate (GFR) value given by inulin clearance. Repeatability, uncertainty and the beta-expectation limits were evaluated from pre-determined serum and urine pools of inulin. Agreement between the two methods was analyzed from 99 inulin clearances performed in renal transplant patients. Impact of the method of dosage on GFR evaluation was simulated according to the respective beta-expectations limits of each method. Overall, intra-assay coefficient of variability and relative bias were inferior to 5% and 10% for both methods. Contrary to the acid method, analytical performance of the enzymatic method was not influenced by the presence of glucose. The relative difference in GFR values obtained with the two methods in transplant patients was − 0.4 ± 10%. Simulations suggested that changes in inulin concentration attributable to analytical error could modify the value of GFR from − 12% to + 28%. In conclusion, while analytical performances are globally acceptable for both methods, they are not strictly equivalent. The impact on the determination of GFR, albeit limited, is not negligible and adds to other sources of inaccuracy. International standardization for the dosage of inulin is necessary. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Peer Reviewed
See detailCKD-EPI GFR estimating equations in kidney transplantation: which added value for the new cystatin C based equations?
Masson, I; Maillard, N; Kamar, K et al

Poster (2012)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailPerformance, limitations and utility of cystatin C as an endogenous GFR marker in renal transplantation
Masson, I; Maillard, N; Tack, I et al

Poster (2012)

Detailed reference viewed: 1 (0 ULg)